SCHEMBL5585573

SCHEMBL5585573

O=C(O)c1ccc(Nc2nc(-c3cccc(OCc4ccc(C5CCCCC5)cc4)c3)cs2)cc1

nearest known ligand 0.61

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CSNK2A1 P68400 11/20 0.61
CSNK2A2 P19784 1/20 0.54
CSNK2B P67870 1/20 0.54
CSNK2A3 Q8NEV1 1/20 0.54
NPC1 O15118 3/20 0.52
RAB9A P51151 3/20 0.52
MAPT P10636 2/20 0.52
MEN1 O00255 1/20 0.52
KMT2A Q03164 1/20 0.52
SMN1; SMN2 Q16637 1/20 0.52
CFTR P13569 1/20 0.51
AMY1A P0DUB6 1/20 0.44
TYR P14679 1/20 0.44
SPHK2 Q9NRA0 2/20 0.44
SPHK1 Q9NYA1 2/20 0.44
GAA P10253 1/20 0.44
NPSR1 Q6W5P4 1/20 0.44
VCP P55072 1/20 0.43
NAMPT P43490 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5585929 0.90 CSNK2A1 (0.58) CSNK2A1CSNK2A2CSNK2BCSNK2A3NPC1
SCHEMBL5585490 0.82 KMT2A (0.41) CSNK2A1MEN1KMT2ASMN1; SMN2NPSR1
SCHEMBL5585668 0.82 SMN1; SMN2 (0.43) CSNK2A1NPC1RAB9AMAPTMEN1
SCHEMBL5585540 0.82 MRGPRX4 (0.40) CSNK2A1MAPTMEN1KMT2ASMN1; SMN2
SCHEMBL5585751 0.81 CSNK2A1 (0.59) CSNK2A1NPC1MAPTMEN1KMT2A
SCHEMBL5585526 0.81 CSNK2A1 (0.44) CSNK2A1NPC1RAB9AMAPTMEN1
SCHEMBL5585812 0.80 MEN1 (0.40) CSNK2A1NPC1RAB9AMEN1KMT2A
SCHEMBL5585491 0.80 MEN1 (0.40) CSNK2A1MEN1KMT2ASMN1; SMN2NPSR1
SCHEMBL5585226 0.80 MRGPRX4 (0.39) CSNK2A1MEN1KMT2ASMN1; SMN2NPSR1
SCHEMBL5585783 0.80 MRGPRX4 (0.39) CSNK2A1NPC1RAB9AMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7163952-B2 Azole compound and medicinal use thereof JAPAN TOBACCO INC. (JP) 2007-01-16 US disclosed
US-7163952-B2 Azole compound and medicinal use thereof JAPAN TOBACCO INC. (JP) 2007-01-16 US disclosed
US-7163952-B2 Azole compound and medicinal use thereof JAPAN TOBACCO INC. (JP) 2007-01-16 US disclosed
US-20050065196-A1 Azole compound and medicinal use thereof JAPAN TOBACCO INC. (JP) 2005-03-24 US disclosed
EP-1452530-A1 AZOLE COMPOUND AND MEDICINAL USE THEREOF JAPAN TOBACCO INC. (JP) 2004-09-01 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050065196-A1 Azole compound and medicinal use thereof PTPN7, PTPN1, PTPN5 CSNK2A1 124/4885CSNK2A2 187/4885CSNK2B 146/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.